PDGFRA mutation
|
GIST
|
PDGFRA mutation
|
GIST
|
ripretinib Sensitive: B - Late Trials
|
ripretinib Sensitive: B - Late Trials
|
PDGFRA mutation
|
Gastric Cancer
|
PDGFRA mutation
|
Gastric Cancer
|
imatinib Sensitive: B - Late Trials
|
imatinib Sensitive: B - Late Trials
|
PDGFRA mutation
|
GIST
|
PDGFRA mutation
|
GIST
|
avapritinib Sensitive: C2 – Inclusion Criteria
|
avapritinib Sensitive: C2 – Inclusion Criteria
|
PDGFRA mutation
|
GIST
|
PDGFRA mutation
|
GIST
|
imatinib Sensitive: C2 – Inclusion Criteria
|
imatinib Sensitive: C2 – Inclusion Criteria
|
PDGFRA mutation
|
NSCLC
|
PDGFRA mutation
|
NSCLC
|
nintedanib Sensitive: C3 – Early Trials
|
nintedanib Sensitive: C3 – Early Trials
|
PDGFRA mutation
|
NSCLC
|
PDGFRA mutation
|
NSCLC
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
PDGFRA mutation
|
GIST
|
PDGFRA mutation
|
GIST
|
AZD1775 Sensitive: D – Preclinical
|
AZD1775 Sensitive: D – Preclinical
|
PDGFRA mutation
|
GIST
|
PDGFRA mutation
|
GIST
|
AZD1775 + avapritinib Sensitive: D – Preclinical
|
AZD1775 + avapritinib Sensitive: D – Preclinical
|